Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007-2011

Hepatology Research

Volumn 43, Issue 2, 2013, Pages 106-112

  Shiraki, Makoto ^a   Nishiguchi, Shuhei ^b   Saito, Masaki ^b   Fukuzawa, Yoshitaka ^c   Mizuta, Toshihiko ^d   Kaibori, Masaki ^e   Hanai, Tatsunori ^a   Nishimura, Kayoko ^f   Shimizu, Masahito ^a   Tsurumi, Hisashi ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAGA UNIVERSITY   (Japan)

^e KANSAI MEDICAL UNIVERSITY   (Japan)

^f GIFU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Body mass index; Energy malnutrition; Liver cirrhosis; Protein malnutrition; Quality of life

Indexed keywords

ALBUMIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; ASCITES; BODY MASS; CALORIMETRY; CHILD PUGH SCORE; EDEMA; ENERGY; FEMALE; HUMAN; JAPAN; KWASHIORKOR; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY QUOTIENT; SHORT FORM 8; STANDARD;

EID: 84873968769     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12004     Document Type: Article

References (33)

1. Morgan AG, McAdam WA, Walmsley GR, Horrocks JC, De Dombal FT. Nutrition in cryptogenic cirrhosis and chronic aggressive hepatitis. Gut 1976; 17 (2): 113-118.
2. Müller MJ. Malnutrition in cirrhosis. J Hepatol 1995; 23 (Suppl 1): 31-35.
3. Alberino F, Gatta A, Amodio P etal. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17: 445-450.
4. Tajika M, Kato M, Mohri H etal. Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition 2002; 18 (3): 229-234.
5. Yoshida T, Muto Y, Moriwaki H, Yamato M. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. J Gastroenterol 1989; 24: 692-698.
6. Marchesini G, Bianci G, Merli M etal. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003; 124: 1792-1801.
7. Muto Y, Sato S, Watanabe A etal. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3 (7): 705-713.
8. Fukushima H, Miwa Y, Shiraki M etal. Oral branched-chain amino acid supplementation improves the oxidized/reduced albumin ratio in patients with liver cirrhosis. Hepatol Res 2007; 37 (9): 765-770.
9. Miwa Y, Shiraki M, Kato M etal. Improvement of fuel metabolism by nocturnal energy supplementation in patients with liver cirrhosis. Hepatol Res 2000; 18 (3): 184-189.
10. Nakaya Y, Okita K, Suzuki K etal. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition 2007; 23: 113-120.
11. The Japanese Society of Gastroenterology. Guidelines for the Diagnosis and Treatment of Liver Cirrhosis. Tokyo: Nankodo, 2010. (in Japanese).
12. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002; 26 (Suppl 1): 73-76.
13. ESPEN. Guidelines on enteral nutrition: liver disease. Clin Nutr 2006; 25: 285-294.
14. Moriwaki H, Shiraki M, Fukushima H etal. Long-term outcome of branched-chain amino acid treatment in patients with liver cirrhosis. Hepatol Res 2008; 38 (s1): S102-106.
15. Muto Y, Sato S, Watanabe A etal. Over weight and obesity increase the risk for HCC in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006; 35: 204-214.
16. Hickman IJ, Powell EE, Prins JB etal. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003; 39 (6): 1042-1048.
17. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60 (8): 646-649.
18. Kato M, Miwa Y, Tajika M, Hiraoka T, Muto Y, Moriwaki H. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. Intern Med 1998; 37 (5): 429-434.
19. Müller MJ, Böttcher J, Selberg O etal. Hypermetabolism in clinically stable patients with liver cirrhosis. Am J Clin Nutr 1999; 69 (6): 1194-1201.
20. Süttmann U, Ockenga J, Hoogestraat L etal. Resting energy expenditure and weight loss in human immunodeficiency virus-infected patients. Metabolism 1993; 42 (9): 1173-1179.
21. Turner-Bowker DM, Bayliss MS, Ware JE, Jr. Kosinski M. Usefulness of the SF-8 Health Survey for comparing the impact of migraine and other conditions. Qual Life Res 2003; 12: 1003-1012.
22. Ware JE, Kosinski M, Dewey JE, Gandek B. How to Score and Interpret Single-Item Healthstatus Measures. A Manual for Users of the SF-8TM Health Survey. Lincoln, RI: QualityMetric Inc., 2001.
23. Kuroda H, Ushio A, Miyamoto Y etal. Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. J Gastroenterol Hepatol 2010; 25 (9): 1550-1555.
24. Fukuhara S, Suzukamo Y. Manual of the SF-8 Japanese Version. Kyoto: Institute for Health Outcome and Process Evaluation Research, 2004. (in Japanese).
25. Health and Welfare Statistics Association. Journal of Health and Welfare Statistics 2010/2011. Tokyo: Kosaido, 2011. (in Japanese).
26. Michitaka K, Nishiguchi S, Aoyagi Y etal. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2010; 45 (1): 86-94.
27. Yoshiji H, Noguchi R, Kitade M etal. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 2009; 44 (5): 483-491.
28. Iwasa J, Shimizu M, Shiraki M etal. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci 2010; 101 (2): 460-467.
29. Nair S, Mason A, Eason J etal. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36 (1): 150-155.
30. Pelletier SJ, Schaubel DE, Wei G etal. Effect of body mass index on the survival benefit of liver transplantation. Liver Transpl 2007; 13 (12): 1678-1683.
31. Thuluvath PJ. Morbid obesity and gross malnutrition are both poor predictors of outcomes after liver transplantation: what can we do about it? Liver Transpl 2009; 15 (8): 838-841.
32. Oza N, Eguchi Y, Mizuta T etal. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol 2009; 44 (12): 1203-1208.
33. Hickman IJ, Jonsson JR, Prins JB etal. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53 (3): 413-419.